Adverse reactions of arsenic in the treatment of acute promyelocytic leukemia and the prevention and treatment of traditional Chinese medicine

Guang-da LI; Rui-bai LI; Yi-ming PAN; Wei MA; Yu LIU; Jing XU; Xin-yi CHEN; Li HOU

doi:10.16025/j.1674-1307.2022.08.027

您当前的位置：

首页 >

文章列表页 >

Adverse reactions of arsenic in the treatment of acute promyelocytic leukemia and the prevention and treatment of traditional Chinese medicine

更新时间：2023-02-15

- Adverse reactions of arsenic in the treatment of acute promyelocytic leukemia and the prevention and treatment of traditional Chinese medicine
- Beijing Journal of Traditional Chinese Medicine Vol. 41, Issue 8, Pages: 930-934(2022)
- 作者机构：
  
  1.北京中医药大学东直门医院血液肿瘤科，北京 100700
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2022.08.027
  CLC：
扫描看全文
李光达，李蕊白，潘一鸣，等.砷剂治疗急性早幼粒细胞白血病的不良反应与中医防治［J］.北京中医药，2022，41（8）：930-934.

LI Guang-da,LI Rui-bai,PAN Yi-ming,et al.Adverse reactions of arsenic in the treatment of acute promyelocytic leukemia and the prevention and treatment of traditional Chinese medicine[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(08):930-934.
李光达，李蕊白，潘一鸣，等.砷剂治疗急性早幼粒细胞白血病的不良反应与中医防治［J］.北京中医药，2022，41（8）：930-934. DOI： 10.16025/j.1674-1307.2022.08.027.

LI Guang-da,LI Rui-bai,PAN Yi-ming,et al.Adverse reactions of arsenic in the treatment of acute promyelocytic leukemia and the prevention and treatment of traditional Chinese medicine[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(08):930-934. DOI： 10.16025/j.1674-1307.2022.08.027.

摘要

三氧化二砷（ATO）、复方黄黛片等砷剂的临床应用使急性早幼粒细胞白血病（APL）治愈成为可能，但治疗过程中会出现肝损害、心脏毒性及分化综合征等不良反应，影响患者预后及生活质量。总结砷剂治疗APL所致不良反应症状、机制、处理、预后以及中医药防治的独特优势与经验，为砷剂治疗APL所致不良反应的中医药防治提供参考。

Abstract

关键词

急性早幼粒细胞白血病三氧化二砷复方黄黛片不良反应中医药

Keywords

references

CHEN Y,KANTARJIAN H,WANG H,et al.Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States,1975-2008[J].Cancer,2012,118(23):5811-5818.

WANG QQ,HUA HY,NARANMANDURA H,et al. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia[J].Toxicol Appl Pharmacol,2020,409:115299.

GILL H,KUMANA CR,YIM R,et al.Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia:A 5-year prospective study[J].Cancer,2019,125(17):3001-3012.

ZHU HH,WU DP,DU X,et al.Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial[J].Lancet Oncol,2018,19(7):871-879.

ILAND HJ,COLLINS M,BRADSTOCK K,et al.Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial[J].Lancet Haematol,2015,2(9):e357-e366.

孙佳富，孙潇，孙桂波，等.三氧化二砷肝毒性及其防治研究进展[J].中国药物警戒,2020,17(3):177-183.

杨琪玫，李娟，罗绍凯，等.三氧化二砷治疗急性早幼粒细胞白血病心脏副作用临床观察[J].中国肿瘤临床与康复,2009,16(2):134-137.

LO-COCO F,CICCONI L,BRECCIA M.Current standard treatment of adult acute promyelocytic leukaemia[J].Br J Haematol,2016,172(6):841-854.

VINEETHA VP,RAGHU KG.An overview on arsenic trioxide-induced cardiotoxicity[J].Cardiovasc Toxicol,2019,19(2):105-119.

UNNIKRISHNAN D,DUTCHER JP,VARSHNEYA N,et al.Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide[J].Blood,2001,97(5):1514-1516.

WESTERVELT P,BROWN RA,ADKINS DR,et al.Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide[J].Blood,2001,98(2):266-271.

LANCET JE,MOSELEY AB,COUTRE SE,et al.A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)[J].Blood Adv,2020,4(8):1683-1689.

LOU Y,TONG H,YU W,et al.Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia[J].Leuk Res,2019,83:106168.

屈敏，梁华，张涛，等.复方黄黛片治疗急性早幼粒细胞白血病疗效分析[J].中华中医药学刊,2018,36(7):1683-1686.

ROBOZ GJ,RITCHIE EK,CARLIN RF,et al.Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide[J].J Clin Oncol,2014,32(33):3723-3728.

FAN L,ZHANG Y,SHI D,et al.Hypoxia enhances the cytotoxic effect of As(4)S(4) on rat ventricular H9c2 cells through activation of ubiquitin-proteasome system[J].J Trace Elem Med Biol,2021,66:126720.

MONTESINOS P,BERGUA JM,VELLENGA E,et al.Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy:characteristics, outcome, and prognostic factors[J].Blood,2009,113(4):775-783.

SANZ M A,MONTESINOS P.How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia[J].Blood,2014,123(18):2777-2782.

ABAZA Y,KANTARJIAN H,GARCIA-MANERO G,et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab[J].Blood,2017,129(10):1275-1283.

STAHL M,TALLMAN MS.Differentiation syndrome in acute promyelocytic leukaemia[J].Br J Haematol,2019,187(2):157-162.

SANZ MA,LO CF,MARTÍN G,et al.Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups[J].Blood,2000,96(4):1247-1253.

KARUNAKARAN P,YANAMANDRA U, NAMPOOTHIRI RV,et al.Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia[J].Br J Haematol,2019,184(4):672-673.

SANZ MA,GRIMWADE D,TALLMAN MS,et al.Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet[J].Blood,2009,113(9):1875-1891.

ZHU HH,HU J,LO-COCO F,et al.The simpler, the better: oral arsenic for acute promyelocytic leukemia[J].Blood,2019,134(7):597-605.

SANZ MA,FENAUX P,TALLMAN MS,et al.Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet[J].Blood,2019,133(15):1630-1643.

CREUTZIG U,DWORZAK MN,BOCHENNEK K,et al. First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid[J].Pediatr Blood Cancer,2017,64(8).doi:10.1002/pbc.26461http://dx.doi.org/10.1002/pbc.26461.

ZHANG L,ZOU Y,CHEN Y,et al.Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial[J].BMC Cancer,2018,18(1):374.

ZHOU J,MENG R,SUI X,et al.Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis[J].Haematologica,2005,90(9):1277-1279.

DE LA SERNA J,MONTESINOS P,VELLENGA E,et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin[J].Blood,2008,111(7):3395-3402.

HOU J,WANG S,ZHANG Y,et al.Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide[J].Ann Hematol,2017,96(12):2005-2013.

王巍,孟然,李丽敏，等.急性早幼粒细胞白血病死亡原因分析[J].哈尔滨医科大学学报,2003,37(1):78-79.

YANG MH,WAN WQ,LUO JS,et al.Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study[J].Am J Hematol,2018,93(12):1467-1473.

GILL H,YIM R,LEE H,et al.Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens:A 15-year prospective study[J].Cancer,2018,124(11):2316-2326.

DAS A,SANYAL T,BHATTACHARJEE P,et al.Depletion of S-adenosylmethionine pool and promoter hypermethylation of Arsenite methyltransferase in arsenic-induced skin lesion individuals:A case-control study from West Bengal, India[J].Environ Res,2021,198:111184.

徐焕华.基于药物代谢途径研究复方黄黛片配伍减毒增效[D].广州:广东药科大学,2018.

孙宇婷.雄黄肠道毒性及丹参配伍减毒研究[D].合肥:安徽医科大学,2020.

黄亚男.防风及其成分对三氧化二砷诱导的毒性和HL-60/H9c2细胞凋亡的影响[D].北京：中国中医科学院,2014.

殷晨晖.HPLC-MS测定桔梗皂苷D分析方法的建立及其在雄黄—桔梗药动学研究中的应用[D].沈阳：中国医科大学,2020.

孙菡，刘婧，吴志瑰，等.南天竹不同药用部位对三氧化二砷肝毒与肾毒的保护作用[J].中国实验方剂学杂志,2020,26(9):136-142.

宋如珺，徐德生，刘力.含雄黄复方制剂的安全性及组方配伍对雄黄减毒作用的研究进展[J].上海医药,2016,37(3):31-34.

李明，王树庆，王晓宝.补阳还五汤对亚砷酸治疗急性早幼粒细胞白血病患者的心脏保护作用[J]. 广州中医药大学学报,2021,38(7):1325-1329.

ZHAO Z,LI J,ZHENG B,et al.Ameliorative effects and mechanism of crocetin in arsenic trioxide‑induced cardiotoxicity in rats[J].Mol Med Rep,2020,22(6):5271-5281.

LIU Y,LIANG Y,ZHENG B,et al.Protective effects of crocetin on arsenic trioxide-induced hepatic injury: involvement of suppression in oxidative stress and inflammation through activation of nrf2 signaling pathway in rats[J].Drug Des Devel Ther,2020,14:1921-1931.

王真，刘宝文.补髓生血解毒汤降低化疗诱导急性早幼粒细胞白血病毒副反应临床观察[J].实用中医内科杂志,2013,27(10):63-65.

徐莉敏.雷公藤红素抑制反式维甲酸引起的分化综合征及信号转导机制研究[D].上海：第二军医大学,2013.

夏小军，段赟，崔杰，等.中西医结合治疗急性早幼粒细胞白血病49例[J].甘肃医药,2019,38(1):13-15.

周复兴.杀白清瘀汤治疗急性早幼粒细胞白血病合并DIC的临床研究[D].济南：山东中医药大学,2009.

王黎，秦桂芳，柯鸿，等.雷公藤红素对人急性早幼粒细胞白血病SCID小鼠移植瘤模型凝血功能的影响[J].中国中医急症,2019,28(2):232-235.

杨丽红.绿豆对砷中毒的解毒作用研究[J].亚太传统医药,2010,6(8):8-9.

邓媛，姜良铎.解毒方对雄黄致小鼠砷中毒解毒作用的实验研究[J].环球中医药,2009,2(3):182-184.

覃淑云，张树球.茯苓、甘草、银花复方制剂对砷中毒小鼠治疗效果的实验研究[J].工业卫生与职业病,2011,37(6):352-354.

钟萌.雄黄炮制降毒方法的研究进展[J].中国药房,2007,18(33):2633-2635.

李蕊白，潘一鸣，刘宇，等.靛玉红及丹参酮Ⅱa促进雄黄降解突变型PML~(A216T)-RARα的作用机制研究[J].北京中医药,2021,40(5):461-465.

JIANG H,LIANG GW,HUANG XJ,et al.Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia[J].Leuk Res,2015,39(12):1319-1324.

范长生，何敏媚，吴久鸿.复方黄黛片治疗急性早幼粒细胞白血病预算影响分析[J].中国新药杂志,2017,26(10):1219-1224.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Treatment of 2 cases of psoriasis aggravation caused by scuchizumab with traditional Chinese medicine

Progress in diagnosis and treatment of coronary heart disease with integrated traditional Chinese and western medicine

Analysis on meditation rules of TCM in the treatment of opioid induced constipation based on TCM inheritance support system

Discussion on pathogenesis and treatment strategy of hypersecretion of airway mucus in chronic airway inflammatory diseases

Research review on prevention and treatment of bronchiectasis by traditional Chinese medicine

Related Author

No data

Related Institution

北京中医药大学研究生院

首都医科大学附属北京中医医院皮肤科

首都医科大学附属北京中医医院心血管科

天津中医药大学研究生院

川北医学院附属医院

⁰